Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


People In Brief

This article was originally published in The Gray Sheet

Executive Summary

Cerus brings in new blood: William Dawson joins firm Aug. 9 as chief financial officer. Previously, Dawson served as CFO at biopharmaceutical firm Dynavax Technologies Corp., where he spearheaded the creation and $61 mil. IPO of Dynavax Asia. Dawson replaces Gregory Schafer, who had been Cerus' CFO since 1999. Cerus recently inked a marketing and distribution agreement with BioOne Corp for Asian commercialization of its Intercept blood system for pathogen inactivation. The Concord, Calif.-based concern's efforts to bring Intercept to the U.S. market encountered delays when it chose to halt its Phase III trial for the red blood cell pathogen reduction program after two patients developed antibodies (1"The Gray Sheet" March 29, 2004, p. 14)...

You may also be interested in...

People In Brief

FDA external relations: FDA Assistant Commissioner for Public Affairs Lawrence Bachorik will serve as acting associate commissioner for external relations, succeeding Peter Pitts, who left the agency for the public relations firm of Manning Selvage & Lee June 18 (1"The Gray Sheet" June 7, 2004, p. 24). Bachorik has headed FDA's public affairs office since February 2000. FDA Senior Director for Media Affairs Brad Stone will fill in for Bachorik as acting assistant commissioner for public affairs...

“Realistic” CEO Parkinson Will Lead Baxter Through Continued Restructuring

Baxter's decision to tap former Abbott exec Robert Parkinson as chairman and CEO sets the stage for swift operational reforms at the highly diversified firm

Navigant Pathogen Inactivation System Catching Up With Cerus, Vitex

Navigant Biotechnologies is dedicating $10 mil. in 2004 to the development of its Mirasol riboflavin-based pathogen reduction technology (PRT) for platelets and red blood cells

Related Content




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts